UKRI CDT IN Biomedical AI w/ Julien Fauqueur

How BenevolentAI leverages ML and AI to develop life-changing medicines

Join Julien Fauqueur, Lead AI Scientist at BenevolentAI, for a  talk on how BenevolentAI combines AI with cutting edge science to de-risk drug discovery. Julien will give an introduction to BenevolentAI to the UKRI CDT Uni.Ed PhD students, and explore how we use machine learning and natural language processing to extract biomedical facts from literature, identify targets and, identify patient subgroups.

Register here →

Julien Fauqueur

Lead AI Scientist

As Lead AI scientist at BenevolentAI, Julien Fauqueur leads and develops novel NLP methods for Biomedical Information Extraction. He holds a PhD in Computer Science from INRIA (France). While a research associate at the University of Cambridge, then as as a researcher in industry, he delivered innovative products using computer vision and machine learning methods. His work was published in over 25 publications and led to 5 patents.

More Posts

You Might Also Like

BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022